Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

23 Apr 2014

Abstract excerpt

// Anne Y. Saiki 1,* , Sean Caenepeel 1,* , Dongyin Yu 1 , Julie A. Lofgren 1 , Tao Osgood 1 , Rebecca Robertson 1 , Jude Canon 1 , Cheng Su 2 , Adrie Jones 3 , Xiaoning Zhao 3 , Chetan Deshpande 4 , Marc Payton 1 , Jebediah Ledell 5 , Paul E. Hughes 1 and Jonathan D. Oliner 1 1 Department of Oncology Research, Amgen, Thousand Oaks, CA 2 Department of Biostatistics, Amgen, Seattle, WA 3 Department of Molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24810962
DOI: 10.18632/oncotarget.1918

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathwaysPMID 24810962Read ↗

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read ↗

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.Semantic proximity Read ↗

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read ↗

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of ActionSemantic proximity Read ↗

Computational pharmacogenomics screen identifies synergistic statin-compound combinations as anti-breast cancer therapiesSemantic proximity Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

Identifying the determinants of response to MDM2 inhibitionSemantic proximity Read ↗

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSemantic proximity Read ↗

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) AntagonistsSemantic proximity Read ↗

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer TherapySemantic proximity Read ↗

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.